{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T16:43:51Z","timestamp":1795193031059,"version":"4.10.3"},"reference-count":146,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["0058\/2020\/A"],"award-info":[{"award-number":["0058\/2020\/A"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["0018\/2023\/AMJ"],"award-info":[{"award-number":["0018\/2023\/AMJ"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has highlighted the pivotal role of the immune response in determining the progression and severity of viral infections. In this paper, we review the most recent studies on the complicated dynamics between SARS-CoV-2 and the host immune system, highlight the importance of understanding these dynamics in developing effective treatments and formulate potent management strategies for COVID-19. We describe the activation of the host's innate immunity and the subsequent adaptive immune response following infection with SARS-CoV-2. In addition, the review emphasizes the immune evasion strategies of the SARS-CoV-2, including inhibition of interferon production and induction of cytokine storms, along with the resulting clinical outcomes. Finally, we assess the efficacy of current treatment strategies, including antiviral drugs, monoclonal antibodies, and anti-inflammatory treatments, and discuss their role in providing immunity and preventing severe disease.<\/jats:p>","DOI":"10.1093\/pcmedi\/pbae015","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:20:07Z","timestamp":1721341207000},"source":"Crossref","is-referenced-by-count":18,"title":["COVID-19: from immune response to clinical intervention"],"prefix":"10.1093","volume":"7","author":[{"given":"Zheng-yang","family":"Guo","sequence":"first","affiliation":[{"name":"State Key Laboratory of Quality Research in Chinese Medicines, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology , Macau 999078 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-qing","family":"Tang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Quality Research in Chinese Medicines, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology , Macau 999078 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Quality Research in Chinese Medicines, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology , Macau 999078 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Quality Research in Chinese Medicines, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology , Macau 999078 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-xin","family":"Zhuang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Quality Research in Chinese Medicines, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology , Macau 999078 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Quality Research in Chinese Medicines, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology , Macau 999078 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"2024081309373009900_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.46234\/ccdcw2020.017","article-title":"A novel coronavirus genome identified in a cluster of pneumonia cases\u2014Wuhan, China 2019-2020","volume":"2","author":"Tan","year":"2020","journal-title":"China CDC weekly"},{"key":"2024081309373009900_bib2","first-page":"271","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume-title":"Cell","author":"Hoffmann","year":"2020"},{"key":"2024081309373009900_bib3","first-page":"143","article-title":"Neuropilin 1: a novel entry factor for SARS-CoV-2 infection and a potential therapeutic target","volume":"15","author":"Chekol\u00a0Abebe","year":"2021","journal-title":"Biologics: Targets and Therapy"},{"key":"2024081309373009900_bib4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"key":"2024081309373009900_bib5","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"2024081309373009900_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41392-020-00460-9","article-title":"Not only ACE2-the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19","volume":"6","author":"Kyrou","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"2024081309373009900_bib7","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"key":"2024081309373009900_bib8","doi-asserted-by":"crossref","first-page":"100306","DOI":"10.1016\/j.jbc.2021.100306","article-title":"SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis","volume":"296","author":"Bayati","year":"2021","journal-title":"J Biol Chem"},{"key":"2024081309373009900_bib9","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/v13112132","article-title":"Current understanding of the innate control of toll-like receptors in response to SARS-CoV-2 infection","volume":"13","author":"Jung","year":"2021","journal-title":"Viruses"},{"key":"2024081309373009900_bib10","doi-asserted-by":"crossref","first-page":"102964","DOI":"10.1016\/j.ebiom.2020.102964","article-title":"Monocyte activation in systemic Covid-19 infection: assay and rationale","volume":"59","author":"Martinez","year":"2020","journal-title":"EBioMedicine"},{"key":"2024081309373009900_bib11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.humimm.2020.12.010","article-title":"Dynamic changes in monocytes subsets in COVID-19 patients","volume":"82","author":"Qin","year":"2021","journal-title":"Hum Immunol"},{"key":"2024081309373009900_bib12","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/jmv.26776","article-title":"In silico analyses on the comparative sensing of SARS-CoV-2 mRNA by the intracellular TLRs of humans","volume":"93","author":"Choudhury","year":"2021","journal-title":"J Med Virol"},{"key":"2024081309373009900_bib13","doi-asserted-by":"crossref","first-page":"118102","DOI":"10.1016\/j.lfs.2020.118102","article-title":"Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions","volume":"257","author":"Jafarzadeh","year":"2020","journal-title":"Life Sci"},{"key":"2024081309373009900_bib14","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.cell.2020.05.006","article-title":"Host-viral infection maps reveal signatures of severe COVID-19 patients","volume":"181","author":"Bost","year":"2020","journal-title":"Cell"},{"key":"2024081309373009900_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/iid3.402","article-title":"Disease-duration based comparison of subsets of immune cells in SARS CoV-2 infected patients presenting with mild or severe symptoms identifies prognostic markers for severity","volume":"9","author":"Kulkarni-Munje","year":"2021","journal-title":"Immunity, Inflammation and Disease"},{"key":"2024081309373009900_bib16","doi-asserted-by":"crossref","first-page":"e20201387","DOI":"10.1084\/jem.20201387","article-title":"SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4","volume":"218","author":"Onodi","year":"2021","journal-title":"J Exp Med"},{"key":"2024081309373009900_bib17","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024081309373009900_bib18","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"key":"2024081309373009900_bib19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41577-020-0407-1","article-title":"Tissue damage from neutrophil-induced oxidative stress in COVID-19","volume":"20","author":"Laforge","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2024081309373009900_bib20","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/infdis\/jiaa150","article-title":"Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia","volume":"221","author":"Wang","year":"2020","journal-title":"J Infect Dis"},{"key":"2024081309373009900_bib21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cellular & Molecular Immunology"},{"key":"2024081309373009900_bib22","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1172\/JCI138554","article-title":"Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent","volume":"130","author":"Mazzoni","year":"2020","journal-title":"J Clin Invest"},{"key":"2024081309373009900_bib23","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fimmu.2020.01512","article-title":"Flattening the COVID-19 curve with natural killer cell based immunotherapies","volume":"11","author":"Market","year":"2020","journal-title":"Front Immunol"},{"key":"2024081309373009900_bib24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2024081309373009900_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses","volume":"14","author":"de\u00a0Wit","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"2024081309373009900_bib26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1440-1843.2006.00942.x","article-title":"Temporal changes in cytokine\/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome","volume":"11","author":"Chien","year":"2006","journal-title":"Respirol"},{"key":"2024081309373009900_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le\u00a0Bert","year":"2020","journal-title":"Nature"},{"key":"2024081309373009900_bib28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1164\/rccm.202203-0526ED","article-title":"Down to a T: the functional importance of lymphopenia in severe COVID-19","volume":"205","author":"Shahridan\u00a0Faiez","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024081309373009900_bib29","first-page":"pbac014","article-title":"Cytokine storm promoting T cell exhaustion in severe COVID-19 revealed by single cell sequencing data analysis","volume-title":"Precision Clinical Medicine","author":"Yang","year":"2022"},{"key":"2024081309373009900_bib30","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.3390\/ijms23137155","article-title":"Early and polyantigenic CD4 T cell responses correlate with mild disease in acute COVID-19 donors","volume":"23","author":"Tarke","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024081309373009900_bib31","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"2024081309373009900_bib32","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.3390\/cells11172743","article-title":"Immune determinants of viral clearance in hospitalised COVID-19 patients: reduced circulating naive CD4+ T cell counts correspond with delayed viral clearance","volume":"11","author":"Zlei","year":"2022","journal-title":"Cells"},{"key":"2024081309373009900_bib33","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.micinf.2006.05.008","article-title":"Human memory T cell responses to SARS-CoV E protein","volume":"8","author":"Peng","year":"2006","journal-title":"Microbes Infect"},{"key":"2024081309373009900_bib34","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"2024081309373009900_bib35","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/all.15372","article-title":"T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19","volume":"77","author":"Taeschler","year":"2022","journal-title":"Allergy"},{"key":"2024081309373009900_bib36","doi-asserted-by":"crossref","first-page":"101495","DOI":"10.1016\/j.trim.2021.101495","article-title":"T helper type (Th1\/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: from cytokines produced to immune responses","volume":"70","author":"Aleebrahim-Dehkordi","year":"2022","journal-title":"Transpl Immunol"},{"key":"2024081309373009900_bib37","doi-asserted-by":"crossref","first-page":"624483","DOI":"10.3389\/fcimb.2021.624483","article-title":"T-helper cell subset response is a determining factor in COVID-19 progression","volume":"11","author":"Gil-Etayo","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2024081309373009900_bib38","doi-asserted-by":"crossref","first-page":"2058738420966497","DOI":"10.1177\/2058738420966497","article-title":"Immune system changes during COVID-19 recovery play key role in determining disease severity","volume":"34","author":"Fathi","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2024081309373009900_bib39","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1038\/s41467-020-17292-4","article-title":"Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia","volume":"11","author":"De\u00a0Biasi","year":"2020","journal-title":"Nat Commun"},{"key":"2024081309373009900_bib40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.025","article-title":"MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile","volume":"104","author":"Mahallawi","year":"2018","journal-title":"Cytokine"},{"key":"2024081309373009900_bib41","doi-asserted-by":"crossref","first-page":"e00165","DOI":"10.1128\/mBio.00165-13","article-title":"Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus","volume":"4","author":"Josset","year":"2013","journal-title":"mBio"},{"key":"2024081309373009900_bib42","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/thoraxjnl-2021-217724","article-title":"Altered distribution, activation and increased IL-17 production of mucosal-associated invariant T cells in patients with acute respiratory distress syndrome","volume":"77","author":"Kim","year":"2022","journal-title":"Thorax"},{"key":"2024081309373009900_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-021-02562-9","article-title":"The cross talk between gastric cancer stem cells and the immune microenvironment: a tumor-promoting factor","volume":"12","author":"Becerril-Rico","year":"2021","journal-title":"Stem Cell Research & Therapy"},{"key":"2024081309373009900_bib44","doi-asserted-by":"crossref","first-page":"e0273186","DOI":"10.1371\/journal.pone.0273186","article-title":"Excessive neutrophil recruitment promotes typical T-helper 17 responses in Coronavirus disease 2019 patients","volume":"17","author":"Choto","year":"2022","journal-title":"PLoS One"},{"key":"2024081309373009900_bib45","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.cell.2020.10.001","article-title":"Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4(+) T cells in COVID-19","volume":"183","author":"Meckiff","year":"2020","journal-title":"Cell"},{"key":"2024081309373009900_bib46","doi-asserted-by":"crossref","first-page":"589380","DOI":"10.3389\/fimmu.2020.589380","article-title":"T-cell hyperactivation and paralysis in severe COVID-19 infection revealed by single-cell analysis","volume":"11","author":"Kalfaoglu","year":"2020","journal-title":"Front Immunol"},{"key":"2024081309373009900_bib47","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/pathogens9121027","article-title":"Mechanisms of dysregulated humoral and cellular immunity by SARS-CoV-2","volume":"9","author":"Taefehshokr","year":"2020","journal-title":"Pathogens"},{"key":"2024081309373009900_bib48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/vaccines11010101","article-title":"Updated insights into the T cell-mediated immune response against SARS-CoV-2: a step towards efficient and reliable vaccines","volume":"11","author":"Dhawan","year":"2023","journal-title":"Vaccines"},{"key":"2024081309373009900_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1172\/jci.insight.128076","article-title":"Follicular regulatory T cells inhibit the development of granzyme B\u2013expressing follicular helper T cells","volume":"4","author":"Xie","year":"2019","journal-title":"JCI insight"},{"key":"2024081309373009900_bib50","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1172\/JCI141054","article-title":"Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals","volume":"130","author":"Gong","year":"2020","journal-title":"J Clin Invest"},{"key":"2024081309373009900_bib51","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Moderbacher","year":"2020","journal-title":"Cell"},{"key":"2024081309373009900_bib52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41564-020-00824-5","article-title":"Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals","volume":"6","author":"Zhang","year":"2021","journal-title":"Nat Microbiol"},{"key":"2024081309373009900_bib53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"2024081309373009900_bib54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41591-020-01143-2","article-title":"Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells","volume":"27","author":"Schulien","year":"2021","journal-title":"Nat Med"},{"key":"2024081309373009900_bib55","first-page":"158","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume-title":"Cell","author":"Sekine","year":"2020"},{"key":"2024081309373009900_bib56","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.immuni.2020.07.026","article-title":"Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses","volume":"53","author":"Zhou","year":"2020","journal-title":"Immunity"},{"key":"2024081309373009900_bib57","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1038\/s41467-020-17240-2","article-title":"Immunological and inflammatory profiles in mild and severe cases of COVID-19","volume":"11","author":"Song","year":"2020","journal-title":"Nat Commun"},{"key":"2024081309373009900_bib58","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"key":"2024081309373009900_bib59","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"2024081309373009900_bib60","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"2024081309373009900_bib61","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"2024081309373009900_bib62","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1038\/s41467-022-32324-x","article-title":"COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation","volume":"13","author":"Reinscheid","year":"2022","journal-title":"Nat Commun"},{"key":"2024081309373009900_bib63","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","article-title":"Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine","volume":"597","author":"Oberhardt","year":"2021","journal-title":"Nature"},{"key":"2024081309373009900_bib64","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/cells11010067","article-title":"Elucidating T cell and B cell responses to SARS-CoV-2 in humans: gaining insights into protective immunity and immunopathology","volume":"11","author":"Khanolkar","year":"2021","journal-title":"Cells"},{"key":"2024081309373009900_bib65","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00705-023-05773-y","article-title":"B lymphocytes in COVID-19: a tale of harmony and discordance","volume":"168","author":"Mansourabadi","year":"2023","journal-title":"Arch Virol"},{"key":"2024081309373009900_bib66","doi-asserted-by":"crossref","first-page":"eabe0367","DOI":"10.1126\/sciimmunol.abe0367","article-title":"Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients","volume":"5","author":"Iyer","year":"2020","journal-title":"Sci Immunol"},{"key":"2024081309373009900_bib67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/joim.13387","article-title":"Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19","volume":"291","author":"Havervall","year":"2022","journal-title":"J Intern Med"},{"key":"2024081309373009900_bib68","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41392-021-00559-7","article-title":"Longitudinal dynamics of antibody responses in recovered COVID-19 patients","volume":"6","author":"Cheng","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"2024081309373009900_bib69","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3201\/eid2701.203515","article-title":"Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection","volume":"27","author":"Choe","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2024081309373009900_bib70","doi-asserted-by":"crossref","first-page":"952697","DOI":"10.3389\/fmed.2022.952697","article-title":"Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection","volume":"9","author":"Mu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024081309373009900_bib71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4049\/jimmunol.2100707","article-title":"Beyond good and evil: molecular mechanisms of type I and III IFN functions","volume":"208","author":"Dowling","year":"2022","journal-title":"J Immunol"},{"key":"2024081309373009900_bib72","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"2024081309373009900_bib73","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.4049\/jimmunol.182.2.1099","article-title":"Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection","volume":"182","author":"Cervantes-Barrag\u00e1n","year":"2009","journal-title":"J Immunol"},{"key":"2024081309373009900_bib74","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1128\/JVI.01794-07","article-title":"Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells","volume":"82","author":"Ireland","year":"2008","journal-title":"J Virol"},{"key":"2024081309373009900_bib75","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","article-title":"Genetic mechanisms of critical illness in COVID-19","volume":"591","author":"Pairo-Castineira","year":"2021","journal-title":"Nature"},{"key":"2024081309373009900_bib76","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"2024081309373009900_bib77","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41587-021-01037-9","article-title":"Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children","volume":"40","author":"Loske","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2024081309373009900_bib78","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1016\/j.csbj.2021.07.023","article-title":"Immune evasion of SARS-CoV-2 from interferon antiviral system","volume":"19","author":"Min","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"2024081309373009900_bib79","first-page":"178","article-title":"Innate immune evasion strategies of SARS-CoV-2","volume":"21","author":"Minkoff","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2024081309373009900_bib80","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41564-021-00884-1","article-title":"ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity","volume":"6","author":"Liu","year":"2021","journal-title":"Nat Microbiol"},{"key":"2024081309373009900_bib81","doi-asserted-by":"crossref","first-page":"198074","DOI":"10.1016\/j.virusres.2020.198074","article-title":"The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway","volume":"286","author":"Li","year":"2020","journal-title":"Virus Res"},{"key":"2024081309373009900_bib82","doi-asserted-by":"crossref","first-page":"28344","DOI":"10.1073\/pnas.2016650117","article-title":"SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling","volume":"117","author":"Miorin","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024081309373009900_bib83","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1261\/rna.078923.121","article-title":"SARS-CoV-2 infection triggers widespread host mRNA decay leading to an mRNA export block","volume":"27","author":"Burke","year":"2021","journal-title":"RNA"},{"key":"2024081309373009900_bib84","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s12276-021-00602-1","article-title":"Innate immune sensing of coronavirus and viral evasion strategies","volume":"53","author":"Kasuga","year":"2021","journal-title":"Exp Mol Med"},{"key":"2024081309373009900_bib85","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1002\/jmv.27050","article-title":"SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I\/MDA-5\u2013MAVS, TLR3\u2013TRIF, and cGAS\u2013STING signaling pathways","volume":"93","author":"Han","year":"2021","journal-title":"J Med Virol"},{"key":"2024081309373009900_bib86","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.celrep.2020.108185","article-title":"SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant","volume":"32","author":"Konno","year":"2020","journal-title":"Cell Rep"},{"key":"2024081309373009900_bib87","doi-asserted-by":"crossref","first-page":"e2101161118","DOI":"10.1073\/pnas.2101161118","article-title":"Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein","volume":"118","author":"Hsu","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024081309373009900_bib88","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"2024081309373009900_bib89","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"2024081309373009900_bib90","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del\u00a0Valle","year":"2020","journal-title":"Nat Med"},{"key":"2024081309373009900_bib91","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00005-023-00673-0","article-title":"Immunity in SARS-CoV-2 infection: clarity or mystery? A broader perspective in the third year of a worldwide pandemic","volume":"71","author":"Kapten","year":"2023","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"2024081309373009900_bib92","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10787-022-00992-2","article-title":"COVID-19 and the role of cytokines in this disease","volume":"30","author":"Hasanvand","year":"2022","journal-title":"Inflammopharmacology"},{"key":"2024081309373009900_bib93","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ijms22010321","article-title":"MicroRNAs and sepsis-induced cardiac dysfunction: A systematic review","volume":"22","author":"Manetti","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024081309373009900_bib94","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","article-title":"Diverse functional autoantibodies in patients with COVID-19","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"2024081309373009900_bib95","doi-asserted-by":"crossref","first-page":"eabl4340","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in\u223c 4% of uninfected individuals over 70 years old and account for\u223c 20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"key":"2024081309373009900_bib96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41421-021-00258-1","article-title":"Distinct uptake, amplification, and release of SARS-CoV-2 by M1 and M2 alveolar macrophages","volume":"7","author":"Lv","year":"2021","journal-title":"Cell Discov"},{"key":"2024081309373009900_bib97","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2024081309373009900_bib98","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jmii.2020.05.001","article-title":"A systematic review of asymptomatic infections with COVID-19","volume":"54","author":"Gao","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"2024081309373009900_bib99","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/CM9.0000000000000798","article-title":"A confirmed asymptomatic carrier of 2019 novel coronavirus","volume":"133","author":"Luo","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"2024081309373009900_bib100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10238-020-00671-y","article-title":"Emerging treatment strategies for COVID-19 infection","volume":"21","author":"Gavriatopoulou","year":"2021","journal-title":"Clin Exp Med"},{"key":"2024081309373009900_bib101","doi-asserted-by":"crossref","first-page":"18951","DOI":"10.1073\/pnas.2009017117","article-title":"Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19","volume":"117","author":"Cauchois","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024081309373009900_bib102","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1186\/s13054-020-03364-w","article-title":"Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study","volume":"24","author":"Kooistra","year":"2020","journal-title":"Crit Care"},{"key":"2024081309373009900_bib103","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jama.2021.9508","article-title":"Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial","volume":"326","author":"Caricchio","year":"2021","journal-title":"JAMA"},{"key":"2024081309373009900_bib104","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"2024081309373009900_bib105","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"key":"2024081309373009900_bib106","first-page":"529","article-title":"Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19","volume":"38","author":"Sciascia","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2024081309373009900_bib107","doi-asserted-by":"crossref","first-page":"586221","DOI":"10.3389\/fmed.2020.586221","article-title":"Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis","volume":"7","author":"Boregowda","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2024081309373009900_bib108","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/jmv.26062","article-title":"COVID-19 pneumonia treated with sarilumab: a clinical series of eight patients","volume":"92","author":"Benucci","year":"2020","journal-title":"J Med Virol"},{"key":"2024081309373009900_bib109","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","article-title":"American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States","volume":"25","author":"Mahmoudjafari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024081309373009900_bib110","first-page":"e32","article-title":"VDDB: A comprehensive resource and machine learning tool for antiviral drug discovery","volume-title":"MedComm\u2013Future Medicine","author":"Tao","year":"2023"},{"key":"2024081309373009900_bib111","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2024081309373009900_bib112","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"JAMA"},{"key":"2024081309373009900_bib113","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41551-020-00633-5","article-title":"Open resource of clinical data from patients with pneumonia for the prediction of COVID-19 outcomes via deep learning","volume":"4","author":"Ning","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"2024081309373009900_bib114","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"2024081309373009900_bib115","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI117881","article-title":"High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG","volume":"95","author":"Ross","year":"1995","journal-title":"J Clin Invest"},{"key":"2024081309373009900_bib116","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"key":"2024081309373009900_bib117","doi-asserted-by":"crossref","first-page":"107205","DOI":"10.1016\/j.intimp.2020.107205","article-title":"Evaluating the effects of intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial","volume":"90","author":"Tabarsi","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2024081309373009900_bib118","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"2024081309373009900_bib119","doi-asserted-by":"crossref","first-page":"eabe4724","DOI":"10.1126\/sciadv.abe4724","article-title":"JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality","volume":"7","author":"Stebbing","year":"2021","journal-title":"Sci Adv"},{"key":"2024081309373009900_bib120","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet North Am Ed"},{"key":"2024081309373009900_bib121","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with Covid-19 pneumonia","volume":"385","author":"Guimar\u00e3es","year":"2021","journal-title":"N Engl J Med"},{"key":"2024081309373009900_bib122","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3390\/jcm9092961","article-title":"Colchicine to weather the Cytokine storm in hospitalized patients with COVID-19","volume":"9","author":"Brunetti","year":"2020","journal-title":"J Clin Med"},{"key":"2024081309373009900_bib123","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/1440-1681.13488","article-title":"Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"48","author":"Hariyanto","year":"2021","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2024081309373009900_bib124","doi-asserted-by":"crossref","DOI":"10.1021\/acscentsci.0c00272","volume-title":"Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related human Coronavirus Diseases","author":"Liu","year":"2020"},{"key":"2024081309373009900_bib125","first-page":"e39","article-title":"Comparison of the disease severity with infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta and Omicron variants: A meta-analysis","volume-title":"MedComm\u2013Future Medicine","author":"Qiu","year":"2023"},{"key":"2024081309373009900_bib126","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1473-3099(23)00070-1","article-title":"Antiviral and bivalent vaccine efficacy against an omicron XBB. 1.5 isolate","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024081309373009900_bib127","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12985-024-02370-6","article-title":"Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development","volume":"21","author":"Ghasemiyeh","year":"2024","journal-title":"Virol J"},{"key":"2024081309373009900_bib128","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejphar.2014.01.055","article-title":"Combination of N-(3'4'-dimethoxycinnamoyl) anthranilic acid with cyclosporin A treatment preserves immunosuppressive effect and reduces the side effect of cyclosporin A in rat","volume":"728","author":"Xu","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2024081309373009900_bib129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"2024081309373009900_bib130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep"},{"key":"2024081309373009900_bib131","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12026-020-09159-z","article-title":"Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview","volume":"68","author":"Ali","year":"2020","journal-title":"Immunol Res"},{"key":"2024081309373009900_bib132","doi-asserted-by":"crossref","first-page":"106924","DOI":"10.1016\/j.intimp.2020.106924","article-title":"Immunotherapeutic approaches to curtail COVID-19","volume":"88","author":"Owji","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2024081309373009900_bib133","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"2024081309373009900_bib134","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1021\/acsptsci.0c00109","article-title":"SARS-CoV-2 vaccine development: an overview and perspectives","volume":"3","author":"Liu","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2024081309373009900_bib135","first-page":"18","article-title":"Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A review","volume":"49","author":"Sheikhshahrokh","year":"2020","journal-title":"Iran J Public Health"},{"key":"2024081309373009900_bib136","doi-asserted-by":"crossref","first-page":"102792","DOI":"10.1016\/j.jaut.2021.102792","article-title":"Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy","volume":"127","author":"Haque","year":"2022","journal-title":"J Autoimmun"},{"key":"2024081309373009900_bib137","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-020-02544-6","volume-title":"The Coronavirus Is Mutating\u2014Does It Matter?","author":"Callaway","year":"\u00a02020"},{"key":"2024081309373009900_bib138","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/idr13040084","article-title":"COVID-19 vaccine booster: to boost or not to boost","volume":"13","author":"Shekhar","year":"2021","journal-title":"Infect Dis Rep"},{"key":"2024081309373009900_bib139","first-page":"1761","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume-title":"N Engl J Med","author":"Thomas","year":"2021"},{"key":"2024081309373009900_bib140","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/d41586-021-02532-4","article-title":"COVID vaccine immunity is waning\u2014How much does that matter?","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"2024081309373009900_bib141","first-page":"129","article-title":"NICE guideline on long COVID","volume-title":"The Lancet Respiratory medicine","author":"Venkatesan","year":"2021"},{"key":"2024081309373009900_bib142","doi-asserted-by":"crossref","first-page":"n136","DOI":"10.1136\/bmj.n136","article-title":"Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline","volume":"372","author":"Shah","year":"2021","journal-title":"BMJ"},{"key":"2024081309373009900_bib143","doi-asserted-by":"crossref","first-page":"15332","DOI":"10.1038\/s41598-023-42321-9","article-title":"Risk of long COVID main symptoms after SARS-CoV-2 infection: a systematic review and meta-analysis","volume":"13","author":"Marjenberg","year":"2023","journal-title":"Sci Rep"},{"key":"2024081309373009900_bib144","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3947\/ic.2024.0024","article-title":"Updated clinical practice guidelines for the diagnosis and management of long COVID","volume":"56","author":"Seo","year":"2024","journal-title":"Infection & Chemotherapy"},{"key":"2024081309373009900_bib145","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jad.2022.08.045","article-title":"Hardiness moderates the effects of COVID-19 stress on anxiety and depression","volume":"317","author":"Bartone","year":"2022","journal-title":"J Affect Disord"},{"key":"2024081309373009900_bib146","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.3390\/microorganisms11122959","article-title":"Long COVID or Post-COVID-19 condition: past, present and future research directions","volume":"11","author":"Fern\u00e1ndez-de-Las-Pe\u00f1as","year":"2023","journal-title":"Microorganisms"}],"container-title":["Precision Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pcm\/advance-article-pdf\/doi\/10.1093\/pcmedi\/pbae015\/58591758\/pbae015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pcm\/article-pdf\/7\/3\/pbae015\/58804854\/pbae015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pcm\/article-pdf\/7\/3\/pbae015\/58804854\/pbae015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T07:04:40Z","timestamp":1723532680000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pcm\/article\/doi\/10.1093\/pcmedi\/pbae015\/7716697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":146,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/pcmedi\/pbae015","relation":{},"ISSN":["2096-5303","2516-1571"],"issn-type":[{"value":"2096-5303","type":"print"},{"value":"2516-1571","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,18]]},"article-number":"pbae015"}}